SARS-CoV-2 Mpro protease variants of concern display altered viral and host target processing but retain potency towards antivirals
Chen, S. A.; Arutyunova, E.; Lu, J.; Khan, M. B.; Rut, W.; Zmudzinski, M.; Shahbaz, S.; Iyyathurai, J.; Moussa, E.; Turner, Z.; Bai, B.; Lamer, T.; Nieman, J. A.; Vederas, J. C.; Julien, O.; Drag, M.; Elahi, S.; Young, H. S.; Lemieux, M. J.
Show abstract
Main protease of SARS-CoV-2 (Mpro) is the most promising drug target against coronaviruses due to its essential role in virus replication. With newly emerging variants there is a concern that mutations in Mpro may alter structural and functional properties of protease and subsequently the potency of existing and potential antivirals. We explored the effect of 31 mutations belonging to 5 variants of concern (VOC) on catalytic parameters and substrate specificity, which revealed changes in substrate binding and rate of cleavage of a viral peptide. Crystal structures of 11 Mpro mutants provided structural insight into their altered functionality. Additionally, we show Mpro mutations influence proteolysis of an immunomodulatory host protein Galectin-8 (Gal-8) and subsequent significant decrease in cytokine secretion, providing evidence for alterations in escape of host-antiviral mechanisms. Accordingly, mutations associated with the highly virulent Delta VOC resulted in significant increase in Gal-8 cleavage. Importantly, IC50s of nirmatrelvir (Pfizer) and our irreversible inhibitor AVI-8053 demonstrated no changes in potency for both drugs for all mutants, suggesting Mpro will remain a high-priority antiviral drug candidate as SARS-CoV-2 evolves.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A heterocyclic compound inhibits viral release by inducing cell surface BST2/Tetherin/CD317/HM1.24 95%
- Structural basis for Nirmatrelvir in vitro efficacy against SARS-CoV-2 variants 95%
- Interplay between receptor binding, immune escape and protein stability determines the natural selection of SARS-CoV-2 variants 94%
Similar papers in this journal
- Computational and Experimental Identification of Potential Neutralizing Peptides Derived from Human ACE2 Against SARS-CoV-2 Infection 96%
- Mechanism through which retrocyclin targets flavivirus multiplication 95%
- Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity 95%
Similar papers in this journal
- A novel polyubiquitin chain linkage formed by viral Ubiquitin prevents cleavage by deubiquitinating enzymes 94%
- Identifying SARS-CoV-2 Antiviral Compounds by Screening for Small Molecule Inhibitors of Nsp3 Papain-like Protease 94%
- Hemagglutinin of Influenza A, but not of Influenza B and C viruses is acylated by ZDHHC2, 8, 15 and 20 93%
Similar papers in this journal
- Mutating novel interaction sites in NRP1 reduces SARS-CoV-2 spike protein internalization 94%
- Rational Design of the Remdesivir Binding Site in the RNA-dependent RNA Polymerase of SARS-CoV-2: Implications for Potential Resistance 94%
- Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.